New study shows benefits of BioWave’s peripheral nerve stimulation in chronic pain


The peer-reviewed journal Pain and Therapy recently published a new study, titled “Reduced pain and improved function following short-term use of non-invasive BioWave high-frequency peripheral nerve stimulation for pain management”, authored by Alaa Abd-Elsayed (University of Wisconsin School of Medicine and Public Health, Madison, USA) and colleagues.

The paper confirmed the findings of smaller prior studies regarding the benefits of BioWave technology to treat chronic pain, as per a press release from the company.

The size of the patient population (1,511) is among the largest ever studied for non-invasive peripheral nerve stimulation (PNS), BioWave claims. The study looked at the use of the BioWaveHOME device in chronic pain treatment, and found that patients experienced significant reductions in overall pain and medication needs within just two weeks of starting to use this technology.

BioWave is a patented, “smarter” pain-blocking technology that provides immediate, deep, long-lasting relief of severe pain, delivering therapeutic electrical signals to treat chronic, acute or postoperative pain. The company further claims that its technology provides eight hours of pain relief, on average, following a 30-minute treatment, and it is also easy to use at home or on the go.

The main outcomes the study found were:

  • Overall pain reduction after using BioWave for two weeks was 46%
  • The average reduction in pain score was 3.47 points (0–10 scale), which is a significant reduction
  • An improvement in quality of life was reported in 87.6% of patients; 42% of patients reported they were able to eliminate or reduce their medication use
  • More than 97% of patients wanted to continue the BioWave therapy
  • The effect on functional lifestyle—including mood, sleep, standing and sitting—was improved across the board
  • There were no adverse reactions or complications reported in the 1,511 patient outcomes

“Although survey studies have inherent limitations, such as duration and compliance biases with such an overwhelming benefit in every category, we believe that non-invasive neuromodulation therapy is a promising, safe, and cost-effective therapy,” the authors write in their report.

“The recent study confirms the efficacy of our patented high-frequency pain-blocking technology for the treatment of severe chronic pain, and for improvement in function and qualities of life for patients,” said Brad Siff, founder and president of BioWave Corporation.


Please enter your comment!
Please enter your name here